Education
About Us
Working with TipRanks
Follow Us
ArriVent BioPharma, Inc. (AVBP)
NASDAQ:AVBP
Firmonertinib, Egfr-Tki Inhibitor Based On Investigator's Choice
Non-Small-Cell Lung Cancer, Advanced Non-Small-Cell Lung Cancer, Metastatic Non-Small-Cell Lung Cancer, Egfr P-Loop And Alpha C-Helix Compressing, Egfr Pacc, Egfr Uncommon Mutations
Phase III
Recruiting
Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations
Aug 15, 2025
―
Firmonertinib
Nsclc, Adjuvant Treatment
Phase III
Recruiting
A Study to Assess the Efficacy and Safety of Firmonertinib Versus Placebo for Adjuvant Treatment in Participants With Stage IB - IIIB NSCLC With Uncommon Epidermal Growth Factor Receptor (EGFR) Mutations, Following Complete Surgical Resection With or Without Adjuvant Chemotherapy（FIRMOST）
May 20, 2025
―
Platinum-Based Chemotherapy, Furmonertinib 240 Mg Oral, Daily, Furmonertinib 160 Mg Oral, Daily
Advanced Non-small Cell Lung Cancer, Metastatic Non-Small Cell Lung Cancer, Egfr Exon 20 Mutations
Phase III
Active Not Recruiting
Study to Compare Furmonertinib to Platinum-Based Chemotherapy for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations (FURVENT)
Oct 31, 2022
―
Furmonertinib
Non-Small Cell Lung Cancer (Nsclc), Advanced Non-small Cell Lung Cancer, Metastatic Non-Small Cell Lung Cancer, Egfr Exon 20 Mutations, Her2 Exon 20 Mutations, Egfr Uncommon Mutations, Including G719x And S768i
Phase I
Active Not Recruiting
Study of Furmonertinib in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Activating, Including Uncommon, Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) Mutations
Apr 06, 2022
―
FAQ
What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases:
a. Preclinical testing
b. Phase 1 – Safety and dosage
c. Phase 2 – Effectiveness and side effects
d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments
e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
a. Preclinical testing
b. Phase 1 – Safety and dosage
c. Phase 2 – Effectiveness and side effects
d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments
e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does ArriVent BioPharma, Inc. (AVBP) have in its pipeline
AVBP is currently developing the following drugs: Firmonertinib, Egfr-Tki Inhibitor Based On Investigator's Choice, Firmonertinib, Platinum-Based Chemotherapy, Furmonertinib 240 Mg Oral, Daily, Furmonertinib 160 Mg Oral, Daily. These drug candidates are in various stages of clinical development as the company works toward FDA approval.